A single but durable stable disease sends the microcap's stock up 730%.
ApexOnco Front Page
Recent articles
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
Some big deals in the second quarter have raised hopes that takeouts are back.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Regeneron is facing two FDA decisions for its T-cell engagers.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
